These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957 [TBL] [Abstract][Full Text] [Related]
26. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622 [TBL] [Abstract][Full Text] [Related]
27. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589 [TBL] [Abstract][Full Text] [Related]
28. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. Lee JH; Essner R; Torisu-Itakura H; Wanek L; Wang H; Morton DL J Clin Oncol; 2004 Sep; 22(18):3677-84. PubMed ID: 15365064 [TBL] [Abstract][Full Text] [Related]
29. Lymph node status and survival in cutaneous malignant melanoma--sentinel lymph node biopsy impact. Rutkowski P; Nowecki ZI; Nasierowska-Guttmejer A; Ruka W Eur J Surg Oncol; 2003 Sep; 29(7):611-8. PubMed ID: 12943629 [TBL] [Abstract][Full Text] [Related]
30. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Verver D; van Klaveren D; van Akkooi ACJ; Rutkowski P; Powell BWEM; Robert C; Testori A; van Leeuwen BL; van der Veldt AAM; Keilholz U; Eggermont AMM; Verhoef C; Grünhagen DJ Eur J Cancer; 2018 Jun; 96():25-33. PubMed ID: 29660597 [TBL] [Abstract][Full Text] [Related]
31. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515 [TBL] [Abstract][Full Text] [Related]
32. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. Tejera-Vaquerizo A; Nagore E; Puig S; Robert C; Saiag P; Martín-Cuevas P; Gallego E; Herrera-Acosta E; Aguilera J; Malvehy J; Carrera C; Cavalcanti A; Rull R; Vilalta-Solsona A; Lannoy E; Boutros C; Benannoune N; Tomasic G; Aegerte P; Vidal-Sicart S; Palou J; Alos LL; Requena C; Traves V; Pla Á; Bolumar I; Soriano V; Guillén C; Herrera-Ceballos E Eur J Cancer; 2015 Sep; 51(13):1780-93. PubMed ID: 26072362 [TBL] [Abstract][Full Text] [Related]
34. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Nowecki ZI; Rutkowski P; Michej W Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535 [TBL] [Abstract][Full Text] [Related]
35. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514 [TBL] [Abstract][Full Text] [Related]
36. Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma. Lee DY; Lau BJ; Huynh KT; Flaherty DC; Lee JH; Stern SL; O'Day SJ; Foshag LJ; Faries MB J Am Coll Surg; 2016 Jul; 223(1):9-18. PubMed ID: 27236435 [TBL] [Abstract][Full Text] [Related]
37. Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin? Rios-Cantu A; Lu Y; Melendez-Elizondo V; Chen M; Gutierrez-Range A; Fadaki N; Thummala S; West-Coffee C; Cleaver J; Kashani-Sabet M; Leong SPL Clin Exp Metastasis; 2017 Jun; 34(5):345-350. PubMed ID: 28699042 [TBL] [Abstract][Full Text] [Related]
38. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. Cascinelli N; Bombardieri E; Bufalino R; Camerini T; Carbone A; Clemente C; Lenisa L; Mascheroni L; Maurichi A; Pennacchioli E; Patuzzo R; Santinami M; Tragni G J Clin Oncol; 2006 Sep; 24(27):4464-71. PubMed ID: 16983115 [TBL] [Abstract][Full Text] [Related]
39. Deep lymph node metastases in the groin significantly affects prognosis, particularly in sentinel node-positive melanoma patients. Niebling MG; Wevers KP; Suurmeijer AJ; van Ginkel RJ; Hoekstra HJ Ann Surg Oncol; 2015 Jan; 22(1):279-86. PubMed ID: 25008028 [TBL] [Abstract][Full Text] [Related]
40. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]